P RIOR to the late 1980s, there were two primary choices for airway management in patients undergoing general anesthesia; endotracheal intubation or face mask ventilation. Since the introduction of the laryngeal mask airway (LMA) in the late 1980s, supraglottic airways (SGAs) have been used in millions of patients, for management of both normal and difficult airways for patients under general anesthesia, with an excellent record of efficacy and safety. As a salvage strategy for patients with difficult airways, the American Society of Anesthesiologists and the Difficult Airway Society of the United Kingdom have both recommended use of the LMA Classic™ in the cannot intubate, cannot mask-ventilate situation. Accordingly, the LMA Classic™ has become, in recent years, both a primary airway and a rescue device in cannot intubate, cannot ventilate events. [1] [2] [3] [4] Over the past decade, several new SGA devices have been introduced as alternatives to the LMA Classic™. 5 Several factors have stimulated the continuing development of supraglottic airways, in what has evolved into a highly competitive marketplace for the manufacturers of these devices. While insertion success rates with the LMA Classic™ are high, it is nevertheless important to have the availability of alternative SGAs, in the event of failure of the first device. 6 Moreover, the need for disposable devices, to avoid transmission of infective organisms and prion proteins, cannot be ignored. 7 The clinical use of the LMA Classic™ has been extensively reviewed. 6 Several disposable variants of the SGA have been developed including: the Ambu® AuraOnce™ Laryngeal Mask (Ambu Inc, Glen Burnie, MD, USA); Portex® Soft-Seal® Laryngeal Mask (Smiths Medical International Limited, Hythe, UK); and the air-Q™ (Mercury Medical, Clearwater, FL, USA). Their designs, configuration, and usage are similar to the LMA Classic™. There are also several SGAs, similar to the LMA Classic™, whose primary indication is to facilitate passage of an endotracheal tube.
Examples include the Intubating LMA™ (LMA North America Inc., San Diego, CA, USA) and the Cookgas® ILA (Mercury Medical, Clearwater, FL, USA). These devices will not be considered in this article.
Four SGAs exist, which are quite different in design compared to the LMA Classic™. These airway devices include: the Combitube® (Tyco-Kendall-Sheridan, Mansfield, MA, USA); the Laryngeal Tube LT (VBM Medizintechnik GmbH, Sulz, Germany); the Cobra Perilaryngeal Airway-CobraPLA® (Engineered Medical System, Indianapolis, IN, USA); and the Streamlined Liner of Pharyngeal Airway -SLIPA™ (SLIPA Medical Limited, London, UK). As the Combitube® and Laryngeal Tube LT have been recently reviewed elsewhere, 8, 9 this review focuses on the latter two devices.
We identified relevant articles through searches using the following keywords on both Medline and Pubmed: 'Cobra', 'Cobra PLA', 'Cobra-PLA', 'PLA', 'SLIPA™', 'Perilaryngeal airway(s)', 'extraglottic airways',' SGA', and 'Supraglottic airway(s). We completed the search for English language papers published during the years 1996 to 2006; and we hand-searched reference lists of these articles for additional sources. Twenty-six publications were identified for the CobraPLA®, six of which were randomized, controlled trials. Five publications were identified for the SLIPA™; two of these were randomized, controlled trials.
The purpose of this brief review was to compare the design and the technical features, as well as the cumulated, clinical experience between the CobraPLA® and the SLIPA™. The efficacy and the safety of both of these devices were compared to the LMA Classic™.
The CobraPLA® Description
The CobraPLA® is a cuffed, disposable, sterile, and latex free SGA. 5, 10, 11 It is made of polyvinyl chloride and has three main parts: a head, a circumferential pharyngeal cuff, and a breathing tube (Figure 1 ). This SGA is available in eight sizes, and can be used for neonates as well as for infants. The internal diameter of the breathing tube for adults has a range of 10.5 to 12.5 mm and all sizes can be attached to a standard, 15 mm internal diameter connector. Cuff volume ranges from < 8 mL, for neonates, to < 65 and < 85 mL, for small and large adults, respectively. An endotracheal tube of size 8 can be advanced through the CobraPLA® sizes 4-6 (Table I) . In August 2006, the original CobraPLA® was replaced with a second-generation model with a distal curve in the breathing tube to avoid kinking, and softer tubes to aid insertion and to reduce mucosal trauma (personal communication with David Alfery MD, Nashville, TN, USA; inventor of CobraPLA®). The Cobra PLUS, which was introduced quite recently, has the added features of a temperature probe to measure core temperature and a gas sampling line for the three smallest pediatric sizes. 12 To insert the CobraPLA®, the patient's head is placed in full extension, under general anesthesia, with the mouth open, and the mandible pulled upward. The CobraPLA® is inserted without directing towards the hard palate and, when the tip reaches the back of the mouth, it is advanced into the hypopharynx until moderate resistance is felt. Cuff pressure is kept < 25 cm H 2 O. Prior to removal, secretions are suctioned and the cuff is completely deflated.
With respect to contraindications, the CobraPLA® does not protect the airway against gastric regurgitation and pulmonary aspiration. Therefore, its usage should be avoided in patients with aspiration risk. 13 The manufacturer recommends that the airway pressure should be limited to < 20 cm H 2 O.
14 There is no report in the literature regarding usage of the CobraPLA® in the prone position. To avoid complications, proper sizing is recommended; and it is suggested that, when in doubt, practitioners should use the smaller size. 15, 16 Experience from randomized controlled trials The CobraPLA® has been evaluated in six, randomized, controlled trials which are summarized in Table II . van Zundert et al. 17 compared insertion and performance characteristics of the LMA Unique™ (The Laryngeal Mask Company, San Diego, CA, USA), the Portex® Soft-Seal® Laryngeal Mask, and the CobraPLA® in 320 patients. They evaluated the number of insertion attempts and the tactile resistance against the device; and they found that the LMA Unique™ and the Portex® Soft-Seal® laryngeal mask were easier to insert compared to the CobraPLA®. However, the CobraPLA® was associated with higher endoscopic scores and better fibreoptic views of the glottis, in comparisons to other devices. While there was more frequent blood staining with the CobraPLA®, there were no other differences in morbidity. These authors also observed that the cuff sealing pressures were higher with the CobraPLA® and the Soft Seal Laryngeal Mask™ compared to the LMA Unique™.
Kurola et al. 18 compared the performances of paramedical students when using the CobraPLA®, the Laryngeal Tube LT, and the Intubating LMA™ in 96 patients undergoing elective surgeries. While insertion times were similar with the three devices, first time insertion success rates with the CobraPLA® were lower, as compared with the Laryngeal Tube LT and the Intubating LMA™. 18 Gaitini et al. 19 compared the CobraPLA® and the LMA Unique™ in 80 healthy adults undergoing minor surgeries. Insertion times for the CobraPLA® were longer than for the LMA Unique™. While these investigators found the two devices to be similar, with respect to fibreoptic scores and the incidence of postoperative adverse events, such as blood staining or sore throat in recovery room; higher leak pressures were observed with the CobraPLA®.
Turan et al. 20 studied the efficacy of the CobraPLA®, the LMA Classic™, and the Laryngeal Tube LT in 90 healthy patients undergoing short surgical procedures. While insertion times were similar with all three devices, lower success rates, at first insertion attempt, were observed with the LMA Classic™ (57%), as compared to the CobraPLA® (97%). As with other studies, CobraPLA®s were associated with blood staining more frequently, as compared to the LMA Classic™ and the Laryngeal Tube LT.
Akca et al. 21 compared the CobraPLA® and the LMA Classic™ in 81 healthy adults undergoing minor gynecologic, orthopedic, or general surgery procedures. Insertion times for the two devices were not significantly different. The CobraPLA® was found to be comparable to the LMA Classic™, with respect to airway adequacy and recovery characteristics, but superior in terms of airway sealing pressure. Also, gastric insufflation pressures with the CobraPLA® were similar to pressures when using the LMA Classic™. Gaitini et al. 22 compared the CobraPLA®, the LMA Unique™, and the Pharyngeal Airway X press™ (PAX) in 75 healthy individuals. The insertion times they observed with the CobraPLA® and the LMA Unique™ were comparable, and both times were shorter than the mean insertion time observed with the PAX™. This study showed that the first attempt, insertion success rates were highest for the LMA Unique™, followed by the CobraPLA® and the PAX™, respectively. Leak pressures were highest for the CobraPLA®, followed by the PAX™ and the LMA Unique™.
The cumulative evidence, from published, randomized, controlled trials, is that insertion times for the CobraPLA® are comparable to the LMA Classic™, the LMA Unique™, the Intubating LMA™, and the Laryngeal Tube LT; while they are shorter than insertion times for the PAX™. Three of the studies show that airway sealing pressures are higher for the CobraPLA® than for the PAX™, the LMA Unique™, and the LMA Classic™.
19,21,22
Case reports and case series evaluating the CobraPLA® Hemodynamic and respiratory variables were reported to remain stable during insertion of the CobraPLA®, in two preliminary studies and cohort studies involving 34 cases. [23] [24] [25] The success of the CobraPLA®, in achieving effective ventilation, was reported in two cases of the LMA Classic™ failure in patients with head and neck burns, contractures, limited neck extension, and limited mouth opening. 26 Moreover, the CobraPLA® has been reported as being successful in the management of a difficult airway: in single cases of the Intubating LMA TM 's failure as a means of securing the airway; 27 for the difficult to intubate/ventilate scenario; 28 and in the airway management of a neonate with Desbuquois syndrome. 29 Successful, lighted, stylet-guided, tracheal intubation through a CobraPLA® has been reported, after repeated failure to intubate through an Intubating LMA TM . These reports suggest that the CobraPLA® may act as an alternative rescue airway in difficult airway scenarios. There are also reports describing successful maintenance of the airway with the CobraPLA®, during performance of percutaneous, dilatational tracheostomy 24, 25 and percutaneous cricothyroidotomy/tracheostomy. 30, 31 The CobraPLA® has successfully been used as a conduit for flexible bronchoscopy in a child under general anesthesia. 32 There are two reports of aspiration associated with use of the CobraPLA®. 33, 34 Cook et al. 33 reported significant pulmonary aspiration in two of 29 patients undergoing positive pressure ventilation using the CobraPLA®; and the study was terminated. Also, a case of airway obstruction, resulting from epiglottic incarceration, has been reported. 35 There was an isolated report on valve leak with the device, 36 although it was suggested that leaks could occur at the monitoring connection site, rather than from the device itself. 37 
Summary of current experience with the CobraPLA®
The CobraPLA® is a cuffed, pharyngeal sealer, supraglottic airway. The insertion times and the first pass success rates are comparable to the LMA Classic™. The CobraPLA® has been used as a primary device to maintain the airway, during spontaneous and controlled ventilation for short surgical procedures. It has been used in the intensive care unit setting for P n/a P = 0.02 P = 0.97 SLIPA = Streamlined Liner of Pharyngeal Airway™; PLMA = Proseal™ laryngeal mask airway; ETT = endotracheal tube; n/s = not significant; n/a = not available.
airway management of polytraumatized patients, for cardiopulmonary resuscitation, and for difficult airway cases, when endotracheal intubation was not possible. The CobraPLA® may be useful in patients with limited mouth opening, after failure to insert an LMA Classic™; or when there is failure to obtain a good seal with the LMA Classic™. One case report alerts to the potential risk of significant, pulmonary aspiration. The new version, the Cobra PLUS, provides the ability of measuring CO 2 and core temperature via its distal thermistor probe.
The SLIPA™ Description
The Streamlined Liner of the Pharyngeal Airway (SLIPA™) is a non-cuffed, single use, latex-free SGA, similar in design to the LMA Unique™ (Figure 2 ).
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It is fabricated from soft plastic (ethylenevinyl-acetate copolymer) in the shape of a pressurized pharynx. 5, 38, 39 The SLIPA™ comprises a hollow, blow-moulded chamber shaped like a boot, with a toe bridge that seals at the base of the tongue and a heel that anchors the device in position between the esophagus and the nasopharynx. 40 The breathing tube connects the body to a 15-mm connector. 41, 42 The chamber provides a variable capacity of up to 50 mL , for storage of regurgitated liquids from the stomach. 40, 41 There are six adult sizes (47-57) with a colour-coded connector. B The number (in mm) indicates the width at the bridge, which is relevant to the width of thyroid cartilage. 39, 40 Size 47 is suitable for small women and teenagers, whereas sizes 49 and 51 are considered as the LMA Classic™ size 3 equivalents. Sizes 51 and 53 are similar to the LMA size 4, and sizes 55 and 57 are considered similar to size 5 LMA.
B
For insertion, with the patient's head in the sniffing position and under general anesthesia, the toe is slipped into the entrance of the esophagus, where it seals against the cricopharyngeus sphincter. Obstruction, immediately after the insertion, is suggestive of down-folding of the epiglottis and should be corrected by extending the head and performing the jaw thrust maneuver. If the patient wakes up with the SLIPA™ in place, a bite block might be needed. At removal, the heel should be dislodged from the nasopharynx by pulling gently in a caudal and an anterior direction.
The SLIPA™ is not advisable for use in the prone position, when there is risk of pulmonary aspiration, and in cases of abnormal, upper airway anatomy, or when changing the head position during the surgery.
5,B
Clinical trial experience with the SLIPA TM Miller et al. 40 compared the SLIPA™, the LMA Proseal™ and standard endotracheal intubation in 150, healthy, adult females scheduled to undergo laparoscopic, gynecological procedures under general anesthesia. The insertion time was longer than 15 sec in 10% of the SLIPA™ cases and in 18% of the LMA Proseal™ cases. The investigators found that the endotracheal tube provided a superior airway seal compared to both SGAs. However, they found acceptable sealing qualities for the SLIPA™ and the LMA Proseal™ SGAs at fresh gas flow rates < 1 FIGURE 2A and 2B Frontal (left) and lateral (right) views of Streamlined Liner of Phar yngeal Air way™ 1) The toe is positioned at the esophageal entrance.
2) The bridge seals the base of the tongue.
3) The heel sets in nasophar ynx. 4) The proximal shaft is a stiffer breathing tube which leads from the body to the connector. , without significant differences between the two devices. In contrast to the SLIPA™ and the LMA Proseal™, which had similar hemodynamic responses, endotracheal intuition was associated with an increase in systolic blood pressure > 15% after airway instrumentation. Recovery times were shorter when using either SGA, as compared with endotracheal intubation. The combined incidence of early and late sore throats was lowest with the LMA Proseal™ (30%), as compared to either the SLIPA™ (49%) or the endotracheal intubation (57%). 40 Miller et al. 40 compared the SLIPA™ and the LMA Classic™ in 120 healthy adult females undergoing general anesthesia for minor gynecological procedures. Comparable first insertion success rates were found for the LMA Classic™ (95%) and the SLIPA™ (92%). The airway seal was sufficiently effective in both groups to permit reductions of fresh gas flow rates to < 1 L·min -1
. Blood pressure alterations, during airway management, were minor with either device. The SLIPA™ was associated with sore throats in 45% of patients vs 53% of patients with the LMA Classic™. 41 Miller et al. 38 also reported, from a small pilot study of 22 patients evaluating use of the SLIPA™, that insertion times took longer than ten seconds and oxygen saturation decreased to < 95% in only 4.5% of the cases.
Hein et al. 39 undertook a clinical trial on 60 patients, to assess the insertion success and effectiveness of SLIPA™, and observed a first-time insertion success rate of 85% in group A (principal investigator) and 90% in group B (medical officers and anesthesiologists). The lowest oxygen saturation was 93% in group A and 91% in group B. After a second attempt at insertion, the overall success rate was 100% in group A compared to 92.5% in group B. The overall incidence of sore throat (score > 0) and blood on the device was reported. Twenty-three percent of patients experienced sore throat, which was described as mild in the majority of cases. Overall, the SLIPA™ was reported as being reliable and easy to use in both spontaneous and assisted ventilation. Coetzee et al. 42 reported an in vitro study where a flow rate of 30 L·min -1 was generated through the device. There was no significant change in pressure between the two ends of the airway, suggesting that the SLIPA™ would not create turbulent flow at the described flow rates.
Summary of current experience with the SLIPA TM
The SLIPA™ is a single use, latex-free, non-cuffed SGA. It is intended for use as a primary airway device for short surgical procedures, 39 for which the SLIPA™ has similar efficacy and complications, as compared to the LMA Classic™. Even though the SLIPA™ has a chamber with a capacity of approximately 50 mL, which most often exceeds the volume of gastric contents in fasted patients, its efficacy in prevention of aspiration has yet to be proven. More clinical evidence is needed to determine the potential reduction of aspiration risk associated with the SLIPA™. As the overall incidence of gastric aspiration is low, it is likely that surveillance studies will provide the best available evidence.
There are several limitations of this review. The few reported, randomized, controlled trials contain relatively small sample sizes; and not all reports provided clear, sample size calculations to justify their sample size requirements. Secondly, the potential for observer bias must be recognized, as the lead author of two studies was also one of the developers of the device. 40, 41 Thirdly, in several of the cited studies, 40, 41 SGA insertions were performed by anesthesiologists who had a large cumulative experience with SGAs.
Conclusions drawn from these studies may not be broadly applicable to anesthesiologists who use these devices less frequently.
Conclusions
Over the past decade, a number of new SGAs have been introduced as alternatives to the LMA Classic ™. The overall efficacy of the CobraPLA® is comparable to that of the LMA Classic™, with a similar reported complication rate. Notably, the CobraPLA® is designed for single use and provides better airway sealing compared to the LMA Classic™. The SLIPA™ also has an efficacy and favourably low complication profile, similar to that of the LMA Classic™. A distinguishing feature of the SLIPA™ is its unique reservoir chamber, which may, in theory, reduce the risk of pulmonary aspiration. Considering the limited number of subjects who have been evaluated in comparative clinical trials, further studies with larger numbers of patients are warranted, to determine the best SGA with regards to efficacy and safety.
